報價延遲最少15分鐘:2024/12/24 12:58 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
181.78 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.19/-0.44
|
|
企業價值
19.14B
|
| 資產負債 |
|
每股賬面淨值
32.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.46B
|
|
每股收益
17.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:58 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies witha contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue. |